Prosecution Insights
Last updated: May 28, 2026
Application No. 18/034,136

TRUNCATED MODIFIED RECOMBINANT ADAMTS13 AND USES THEREOF

Non-Final OA §102§OTHER
Filed
Apr 27, 2023
Priority
Oct 28, 2020 — provisional 63/106,699 +1 more
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The United States Department of Health and Human Services
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
1m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
541 granted / 893 resolved
+0.6% vs TC avg
Strong +31% interview lift
Without
With
+31.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
44 currently pending
Career history
943
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
60.7%
+20.7% vs TC avg
§102
3.3%
-36.7% vs TC avg
§112
4.1%
-35.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 893 resolved cases

Office Action

§102 §OTHER
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, claims 1 – 5, 7 – 10, 14 and 16 in the reply filed on August 18, 20025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1 – 5, 7 – 10, 14, 16, 19, 22, 36 – 38, 43, 52, 54 – 55 are pending; claims 19, 22, 36 – 38, 43, 52 and 54 – 55 are withdrawn; claims 1 – 5, 7 – 10, 14 and 16 have been considered on the merits. Information Disclosure Statement The information disclosure statement (IDS) submitted on November 7, 2023 and August 18, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Specification The disclosure is objected to because of the following informalities: On pages 2, 5 and 6, “mrADAMST13” is spelled incorrectly. Appropriate correction is required. Claim Objections Claim 1 is objected to because of the following informalities: “mrADAMST13” is spelled incorrectly. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 – 3, 9 – 10, 14 and 16 are rejected under 35 U.S.C. 102a1 and 102a2 as being anticipated by Bare et al. (US 2012/0108651) OR Bancel et al. (US 8999380). Regarding claims 1 – 3, Bare teaches a polypeptide comprising at least 95% of SEQ ID NO:7 (search result 8, SEQ ID 125, 95.1% match); while Bancel teaches a polypeptide comprising at least 95% of SEQ ID NO:7 (search result 1, SEQ ID 780, 95.1% match). These sequences match at least 90%, 92% and 95% and are not SEQ ID NO:5 as disclosed by the specification. Regarding claims 9 – 10, 14 and 16, Bare teaches the polypeptide is recombinant, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid and cells comprising the polypeptide (0039, 0043, p.15); while Bancel teaches the polypeptide is recombinant, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid and cells comprising the polypeptide (col.13 – 14). The references anticipate the claimed subject matter. Allowable Subject Matter Claims 4 – 5 and 7 – 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Apr 27, 2023
Application Filed
Nov 04, 2025
Non-Final Rejection mailed — §102, §OTHER
Apr 29, 2026
Response Filed
May 20, 2026
Examiner Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12635694
MICROBIAL INOCULANT COMPOSITIONS AND METHODS
3y 6m to grant Granted May 26, 2026
Patent 12636321
COMPOSITION
11m to grant Granted May 26, 2026
Patent 12624371
A PROCESS TO TREAT A CARBON DIOXIDE COMPRISING GAS
3y 1m to grant Granted May 12, 2026
Patent 12620244
METHODS AND DEVICES FOR LIVE CELL IMAGING ANALYSIS
5y 9m to grant Granted May 05, 2026
Patent 12618052
ENZYME COMPOSITION TO REDUCE GLUCOSE UPTAKE WITHOUT COMPROMISING TASTE
2y 7m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+31.1%)
3y 2m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 893 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month